Table I.
Demographics and medical history
| Mutually exclusive symptom in last 12 months
|
P valuea | ||||
|---|---|---|---|---|---|
| Stroke (n = 947) | TIA (n = 1449) | TMB (n = 508) | ASX (n = 5736) | ||
| Age, years (range) | 69.7 (29–94) | 71.6 (18–98) | 69.7 (47–94) | 71.2 (39–95) | <.0001 |
| Gender, male (%) | 61.1% (579/947) | 59.8% (866/1449) | 68.3% (347/508) | 58.2% (3336/5736) | <.0001 |
| Race, white | 87.9% (832/947) | 92.8% (1344/1449) | 92.7% (471/508) | 93.7% (5374/5736) | <.0001 |
| Ethnicity, Hispanic | 4.6% (44/947) | 3.1% (45/1449) | 2.8% (14/508) | 3.2% (185/5736) | .1100 |
| Coronary artery disease | 45.3% (429/947) | 49.6% (718/1449) | 47.8% (243/508) | 54.4% (3121/5736) | <.0001 |
| MI | 16.7% (158/947) | 16.7% (242/1449) | 16.9% (86/508) | 19.2% (1104/5736) | .0437 |
| Valvular heart disease | 6.1% (58/947) | 7.5% (109/1449) | 6.5% (33/508) | 7.6% (438/5736) | .3401 |
| Cardiac arrhythmia | 12.2% (116/947) | 13.0% (188/1449) | 12.8% (65/508) | 14.0% (805/5736) | .3684 |
| Congestive heart failure | 10.7% (101/947) | 10.0% (145/1449) | 9.6% (49/508) | 10.0% (574/5736) | .9184 |
| Hypertension | 84.6% (801/947) | 83.8% (1214/1449) | 76.4% (388/508) | 84.7% (4861/5736) | <.0001 |
| Diabetes | 36.3% (344/947) | 32.2% (467/1449) | 28.0% (142/508) | 32.7% (1877/5736) | .0118 |
| Chronic obstructive pulmonary disease | 18.0% (170/947) | 19.3% (280/1449) | 22.6% (115/508) | 17.7% (1013/5736) | .0285 |
| Chronic renal failure | 4.0% (38/947) | 3.5% (50/1449) | 2.0% (10/508) | 3.3% (192/5736) | .2294 |
| Peripheral vascular disease | 33.5% (317/947) | 37.6% (545/1449) | 36.0% (183/508) | 43.9% (2520/5736) | <.0001 |
| Current or past smoker | 59.6% (564/947) | 58.5% (847/1449) | 66.5% (338/508) | 60.9% (3494/5736) | .0120 |
| Cancer | 15.2% (144/947) | 16.9% (245/1449) | 19.1% (97/508) | 14.2% (816/5736) | .0037 |
| Coagulopathy | 1.5% (14/947) | 1.4% (20/1449) | 0.6% (3/508) | 1.3% (72/5736) | .5013 |
| ASA grade | |||||
| ≤3 | 88.1% (834/947) | 91.5% (1326/1449) | 92.9% (472/508) | 92.1% (5282/5736) | .0004 |
| >3 | 11.9% (113/947) | 8.5% (123/1449) | 7.1% (36/508) | 7.9% (454/5736) | |
| New York Heart Association class | |||||
| ≤2 | 93.7% (887/947) | 92.1% (1335/1449) | 93.3% (474/508) | 93.7% (5372/5736) | .2147 |
| >2 | 6.3% (60/947) | 7.9% (114/1449) | 6.7% (34/508) | 6.3% (364/5736) | |
| Aspirin | 79.3% (751/947) | 84.9% (1230/1449) | 82.9% (421/508) | 84.9% (4872/5736) | .0001 |
| Clopidogrel | 46.5% (440/947) | 50.0% (725/1449) | 51.0% (259/508) | 39.0% (2235/5736) | <.0001 |
| Aspirin or clopidogrel | 88.4% (837/947) | 92.0% (1333/1449) | 92.1% (468/508) | 90.3% (5179/5736) | .0146 |
| Age ≥80 years | 20.3% (192/947) | 23.2% (336/1449) | 18.3% (93/508) | 19.5% (1117/5736) | .0115 |
| Embolic protection (CAS only) | 95.8% (322/336) | 97.0% (554/571) | 97.9% (184/188) | 98.0% (1751/1787) | .0992 |
ASA, American Society of Anesthesiologists; ASX, asymptomatic; CAS, carotid artery stenting; MI, myocardial infarction; TIA, transient ischemic attack; TMB, transient monocular blindness.
a
P value for age was found by analysis of variance. All others found by χ2 tests.